Developing GBP-targeted drugs—e.g., GTPase inhibitors for GBP1 in glioblastoma, agonists for GBP2 in breast cancer, or allosteric modulators for GBP5—requires high-throughput screening, molecular docking, and in vivo validation in patient-derived xenografts or organoids to ensure efficacy and tolerability, monitorable through preclinical efficacy trials [36,68]. This evidence concerns the gene GBP1 and glioblastoma.